OXIS International, Inc. (OTCMKTS:OXIS) got a recent boost in volume and price after the Company announced it has entered into an agreement with the University of Minnesota to develop and commercialize cancer therapies using Trispecific Killer Engager (TriKE) technology developed by researchers at the university to target NK cells to cancer.
OXIS has been trading strong as the Company adds new patients to their Phase 1/Phase 2 trial of its most promising cancer drug, OXS-1550. Late last year OXIS received notification from the FDA that they can proceed with their planned combination Phase 1/Phase 2 clinical trial for OXS-1550.
OXIS International, Inc. (OTCMKTS:OXIS) is a biotech company that develops and commercializes innovative drugs of therapeutic molecules including cannabinoids, which are focused on several cancer indications. Oxis address the clinical shortcomings of existing commercial products in related fields. OXIS has formed relationships with some of the world’s leading cannabinoid researchers and institutions to advance its technologies.
The Company has Tony Cataldo behind it who recently said ”As the founder of Lion Biotechnologies, Inc. (LBIO $240 Million market capitalization) I found the same dynamics when creating the nucleus for markets in cell therapies, which brought significant market cap appreciation in exploding biotech sectors. They are now present in the Cannabinoid/Medical Marijuana sector for Oxis Biotech, Inc. to take advantage of.
In September OXIS announced the execution of an exclusive worldwide license agreement to further develop and commercialize DT2219ARL, a novel therapy for the treatment of various human B cell cancers, leukemias and lymphomas.
DT2219ARL is a bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. CD19 is a membrane glycoprotein present on the surface of all stages of B lymphocyte development, and is also expressed on most B-cell mature lymphoma cells and leukemia cells.1 CD22 is a glycoprotein expressed on B-lineage lymphoid precursors, including precursor B acute lymphoblastic leukemia, and often is co-expressed with CD19 on mature B-cell malignancies such as lymphoma.2
To Find out the inside Scoop on OXIS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
On November 23 OXIS announced its collaborators at the University of Minnesota Masonic Cancer Center received notification from the U.S. Food and Drug Administration (FDA) that they can proceed with their planned combination Phase 1/Phase 2 clinical trial for OXS-1550. Oxis holds worldwide exclusive rights to develop and commercialize OXS-1550, a novel therapy for the treatment of leukemia and lymphoma.
OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, they internalize OXS-1550 and are killed due to the action of drug’s cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with B-cell lymphoma or leukemia.
In June OXIS said it has begun enrolling patients in a Phase 1/Phase 2 trial of its most promising cancer drug, OXS-1550. The FDA-approved clinical trial is being conducted at the University of Minnesota’s Masonic Cancer Center under the watch of Dr. Daniel Vallera, a research scientist who developed the drug and is a member of the Scientific Advisory Board of Oxis’ wholly owned subsidiary, Oxis Biotech Inc.
On July 25 OXIS announced its wholly owned subsidiary, Oxis Biotech Inc., has entered into an agreement with the University of Minnesota to develop and commercialize cancer therapies using Trispecific Killer Engager (TriKE) technology developed by researchers at the university to target NK cells to cancer.
CEO Anthony J. Cataldo said the new agreement provides the company with a significant asset. He said TriKE technology is important because it’s highly effective at killing cancer cells with minimal side effects in pre-clinical models.
“The bispecific antibody platform is well known for its ability to kill cancer cells via antibody dependent cell-mediated toxicity (ADCC). However, current successes in immunotherapy indicate that enhanced killing will not be enough. We believe the TriKE platform from University of Minnesota has found a way to expand the immune cell population within the patient, but not at the expense of creating a toxic environment.”
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $6.5 million market valuation OXIS has minimal assets or revenues and significant rising short term debt. At the same time OXIS is an exciting story developing in small caps that just announced it has added 6 new patients in a Phase 1/Phase 2 trial of its most promising cancer drug, OXS-1550. Oxis holds worldwide exclusive rights to develop and commercialize OXS-1550. OXIS has a long way to go with Tony Cataldo as CEO and the Company up listing to the OTCBB. Mr. Cataldo has employed the same strategy he used as founder of LBIO and speculators seem to love the news with OXIS quickly gaining a loyal shareholder base that swears this one goes way higher.We will be updating on OXIS when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with OXIS.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in OXIS either long or short and we have not been compensated for this article.